CLINICAL PHARMACOKINETICS AND PRACTICAL APPLICATIONS OF SIMVASTATIN
Main Article Content
Keywords
simvastatin, pharmacokinetics, clinical, hypercholesterolemia, dosing
Abstract
Clinical pharmacokinetics plays a crucial role in determining the optimal dosage regimen for drugs, including simvastatin, a widely used medication for the management of hypercholesterolemia. This essay aims to provide an overview of the pharmacokinetic properties of simvastatin and its practical applications in clinical settings. The discussion will cover key concepts such as absorption, distribution, metabolism, and excretion of simvastatin, as well as factors influencing its pharmacokinetics. The methodology involves a review of relevant literature from reputable sources to present a comprehensive analysis. The results highlight the significance of understanding simvastatin pharmacokinetics in optimizing therapy outcomes. The discussion will explore the implications of pharmacokinetic principles in dosing strategies and therapeutic monitoring. In conclusion, a better understanding of simvastatin pharmacokinetics is essential for healthcare professionals to ensure safe and effective use of this medication in the management of cardiovascular diseases.
References
2. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-43.
3. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74.
4. Reddy P, Edwards KD, Little JM. The clinical pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343-370.
5. Neuvonen PJ, Niemi M, Backman JT. Drug interactions lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81.
6. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71-105.
7. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
8. Ban GY, Kim SH, Yoo HJ, Kim SN, Shin YS, Park HS. Clinical pharmacogenetics of leukotriene receptor antagonists in asthma. Allergy Asthma Immunol Res. 2014;6(5):383-92.
9. Jiang H, Zhang X, Yu Z. Pharmacokinetic drug-drug interactions of statins involving cytochrome P450 (CYP) and non-CYP pathways. In: Wen X, et al., editors. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. Elsevier; 2011. p. 491-511.
10. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Abdullah Saood Suleman Alharbi
Pharmacy technician, King Khalid Hospital in Al Kharj
Nawaf Abdulaziz Fahad Al-Howidi
pharmacist, King Khalid Hospital in Al Kharj
Saleh Abdullah Mohammed Alwabel
Pharmacy technician, King Khalid Hospital in Al Kharj
Mahdi Ali Hussain Althuwaini
pharmacist , King Khalid Hospital in Al Kharj
Arwa Yousef Faraj Alsomali
Pharmacist, King Khalid Hospital in Al Kharj
Ibrahim abdullah mesfer aldawsari
Pharmacy technician, King Khalid Hospital in Al Kharj